Safety population size and duration of exposure prior to approval of new medicines: A database analysis of medicines centralised approved in the European Union between 2011 and 2023.

Trends in patient exposure prior to approval (2011–2023) The median number of patients exposed to new active substances prior to approval shows a decreasing trend over the period 2011–2023, particularly from 2016 onwards ( Fig 5 ).

also in 47,180 other papers